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Biliary pseudolithiasis has been reported in patients who received ceftriaxone therapy. To examine this
phenomenon further, serial gallbladder sonograms were evaluated in 44 adult patients who received
intravenous ceftriaxone at 2 g or a placebo daily for 14 days in a double-blind controlled study. Ultrasound
examinations of gallbladders were performed on days 1 and 14 of therapy and 2 weeks posttherapy if
abnormalities were observed on day 14. Eight patients were unevaluable because of abnormal base-line
gallbladder sonograms. Thirty-six patients (ceftriaxone, n = 28; placebo, n = 8) demonstrated normal base-
line gallbladder sonograms and were evaluated for the development of change. A total of 6 of 28 (21.4%)
ceftriaxone-treated patients and 1 of 8 (12.5%) patients who received the placebo demonstrated abnormal
gallbladder sonograms on day 14 (P = 0.491). Four of the six ceftriaxone-treated patients demonstrating
abnormal sonograms were clinically asymptomatic, while two patients reported vomiting. The abnormal
sonograms of gallbladders of patients treated with ceftriaxone returned to normal between 9 and 26 days
posttherapy. These data suggest an association between ceftriaxone treatment and the development of
gallbladder abnormalities on ultrasound examination which resolve spontaneously on discontinuation of
ceftriaxone therapy.
The term pseudolithiasis has been used previously (K.
Heim-Duthoy, E. Caperton, G. Matzke, and P. Peterson,
Program Abstr. 28th Intersci. Conf. Antimicrob. Agents
Chemother., abstr. no. 556, 1988) to report the preliminary
findings of the study reported here. Pseudolithiasis was used
to describe sonographic abnormalities in the gallbladders of
patients treated with ceftriaxone in an attempt to differen-
tiate the reversible abnormalities which have been observed
in ceftriaxone-treated patients from those of true operative
stones.
Biliary pseudolithiasis has been reported in patients, in-
cluding children, who have received high-dose intravenous
bolus ceftriaxone therapy (3-5). Although these patients may
or may not demonstrate symptoms, several symptomatic
patients have undergone surgery. It is unclear whether
biliary pseudolithiasis associated with ceftriaxone therapy is
of clinical importance, and the need for surgical intervention
has not been well-defined for individuals in any age group.
This study was designed to (i) determine the frequency of
abnormal findings, including stone(s) as well as sludge, on
gallbladder sonograms (apparent biliary pseudolithiasis) dur-
ing ceftriaxone or placebo treatment in adult patients with
arthritis and positive titers for Lyme disease; (ii) ascertain
the nature and frequency with which symptoms associated
with altered biliary function are present in these patients;
and (iii) evaluate whether the gallbladder abnormalities
which develop during ceftriaxone therapy resolve spontane-
ously upon discontinuation of ceftriaxone.
MATERIALS AND METHODS
Patients 18 years of age or older with two antibody titers to
Borrelia burgdorferi of 1:64 or greater and stable, chronic
arthritis were evaluated in an addendum to a double-blind,
* Corresponding author.
placebo-controlled outpatient study of ceftriaxone efficacy
(unpublished data). Males and nonpregnant, nonlactating
females were eligible to participate in the study if they had
no history of hypersensitivity to cephalosporins. None of the
patients had evidence of hepatic or obstructive biliary dis-
ease or significant renal impairment. No patients had re-
ceived antibiotic therapy within 1 week prior to study
initiation, and none of the patients received other antimicro-
bial agents concurrently. Written, informed consent was
obtained from all patients who participated in the study.
This addendum study in which we evaluated serial gall-
bladder sonograms was initiated midway through an ongo-
ing, larger study assessing ceftriaxone efficacy in patients
with positive titers for the Lyme disease agent, B. burgdor-
feri. At the time of entry into the study, each patient was
randomly assigned to receive ceftriaxone (2 g; Rocephin, lot
no. C126694-01; Hoffmann-La Roche Inc., Nutley, N.J.) or
placebo (0.9% sodium chloride) in a daily 30-min intravenous
infusion for a total treatment duration of 14 days. The
randomization ratio of patients who received ceftriaxone to
those who received placebo in the planned efficacy evalua-
tion was originally 2:1. Patients who received placebo had
the option of subsequently crossing over to receive ceftriax-
one.
Gallbladder ultrasound examinations were performed on
days 1 and 14 of therapy. Patients demonstrating an abnor-
mal gallbladder sonogram on day 1 were excluded from
further evaluation. Follow-up gallbladder ultrasound exam-
inations were completed 2 to 3 weeks posttherapy if abnor-
malities were detected at day 14. Patients with persistent
gallbladder abnormalities were followed until the abnormal-
ity was resolved.
Gallbladder ultrasound examinations were performed with
a sector, real-time ultrasound scanner (Ultramark 4 or 8;
Advanced Technologies Laboratory Machine, Bothell,
Wash.). A 3.0- or 3.5-MHz transducer was used in most
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APPARENT BILIARY PSEUDOLITHIASIS 1147
TABLE 1. Patient demographic characteristicsa
Treatment No. of evalu- Sex Creatinine clearance Treatment
group able patients (M/Fb) Age (yr) (ml/min) Wt (kg) duration (days)
Ceftriaxone 28 8/20 39.8 ± 14.8 105.9 t 23.6 67.9 t 12.4 13.8 t 0.8
Placebo 8 3/5 45.4 t 16.0 87.0 t 40.5 79.3 t 15.0c 14.0 t 0.0
a Values are means ± standard deviations.
b M, Male; F, female.
c p < 0.05.
patients; a 5-MHz transducer was used in thinner patients.
Patients were routinely studied in both the supine and left
posterior oblique positions and, if necessary, in an upright,
sitting position. Longitudinal and transverse images of the
right upper quadrant were obtained, with emphasis on the
gallbladder and biliary tree. Gallstones were diagnosed by
demonstrating intraluminal echoes which had acoustical
shadowing and were usually mobile with patient reposition-
ing. Echogenic bile without acoustical shadowing was con-
sidered sludge. All results were interpreted by the same
investigator, who was blinded to treatment randomization
and treatment order.
Clinical evaluations, i.e., medical history, physical exam-
ination, and laboratory evaluation, were performed prether-
apy, during therapy (day 7), posttherapy, and at the time of
follow-up if symptomatology or sonographic changes were
detected.
Significant differences in demographic characteristics be-
tween groups were assessed by an independent t test. Sex
distribution differences between groups were assessed by a
chi-square analysis. The incidence of gallbladder abnormal-
ity developments in patients who received placebo or ceftri-
axone were evaluated by a chi-square analysis. Statistical
significance was assessed at a level of P < 0.05.
RESULTS
A total of 44 patients were randomized to received either
ceftriaxone or placebo and underwent initial gallbladder
ultrasonography. Eight patients (two who received placebo
and six who received ceftriaxone) were unevaluable because
of abnormal gallbladder sonograms on day 1. The demo-
graphic characteristics of the 36 evaluable patients in the
corresponding treatment groups are presented in Table 1.
Abnormal gallbladder sonograms were demonstrated on
day 14 in 1 of 8 (12.5%) and 6 of 28 (21.4%) evaluable
patients treated with placebo and ceftriaxone, respectively.
The difference between the two groups was not statistically
significant (P = 0.491). The characteristics of the seven
patients who developed apparent biliary pseudolithiasis are
FIG. 1. Sequential gallbladder sonograms for patient 38 on days 1 (A) and 14 (B and C) of therapy and at the time of follow-up (D).
VOL. 34, 1990
 o
n
 N
ovem
ber 24, 2015 by VIRG
INIA CO
M
M
O
NW
EALTH UNIV
http://aac.asm
.org/
D
ow
nloaded from
 
ANTIMICROB. AGENTS CHEMOTHER.
TABLE 2. Characteristics of patients who developed apparent biliary pseudolithiasis
Treatment Dose Clinically Time ofPatient Treatment (Ayge) SeXa Wt Diagnosis duration (mg/kg Sonographic sympto- abnormalityno. group (yr) (kg) (days) per day) interpretation
mai
resolution
30 Ceftriaxone 64 F 64.0 Atypical arthritis 14 31.3 Stones No 24
38 Ceftriaxone 56 F 71.8 Atypical arthritis 14 27.9 Stones Yes 14
41 Ceftriaxone 39 F 61.4 Atypical arthritis 14 32.6 Stones Yes 26
45 Ceftriaxone 37 F 52.7 Vasculitis 14 38.0 Sludge No 9
49 Ceftriaxone 32 F 56.8 Rheumatoid arthritis 14 35.2 Stones No 14
54 Ceftriaxone 54 F 63.6 Rheumatoid arthritis 12 31.4 Single stone No 21
46 Placebo 42 M 90.9 Psoriatic arthritis 14 NAC Sludge No 44
a F, Female; M, male.
b Days after the end of therapy.
c NA, Not applicable.
presented in Table 2. Two patients who received ceftriaxone
and who also developed abnormal gallbladder sonograms
became symptomatic. Shortly after receiving dose 12 of
ceftriaxone, patient 41 developed vomiting, which persisted
for approximately 1 h. However, patient 41 completed the
14-day course of therapy, at which time the sonogram was
interpreted as showing gallstones. Patient 38 experienced
vomiting after dose 14 of ceftriaxone, at which time gall-
stones were diagnosed following ultrasound examination.
No other patients in the study experienced vomiting.
Representative sequential photographs of the gallbladder
abnormality observed in patient 38 are displayed in Fig. 1.
The ultrasound characteristics of patients who developed
apparent biliary pseudolithiasis are given in Table 3.
No significant differences in age, weight, duration of
therapy, or dose were observed between patients who
received ceftriaxone with and without the development of
apparent biliary pseudolithiasis (Table 4). All patients who
developed apparent biliary pseudolithiasis during ceftriax-
one therapy were female (P = 0.08).
DISCUSSION
The development of sediment in the gallbladders of dogs
and baboons that received ceftriaxone was first reported in
1981 (6). This finding appeared to be related to ceftriaxone
dose, the length of ceftriaxone administration, or both.
Chemical analysis of the sediment revealed a predominance
of an insoluble calcium salt of the antibiotic.
In 1986, Schaad et al. (4) reported a case of an 18-year-old
male who developed an abnormal gallbladder sonogram
consistent with gallstones on serial examinations during
ceftriaxone therapy. Ultrasonographic abnormalities nor-
malized on the discontinuation of ceftriaxone. In 1988,
another case report of ceftriaxone-associated cholecystitis
was reported in a 16-year-old female (3). Again, follow-up
ultrasound examination demonstrated marked improvement
at 8 weeks postdischarge. Subsequently, Schaad et al. (5)
prospectively evaluated serial abdominal ultrasonograms in
37 children who received ceftriaxone (60 to 100 mg/kg per
day) for serious infections. Of 37 patients who were evalu-
ated, 16 developed biliary concrements, with 3 patients
developing symptoms. Sonographic abnormalities, symp-
toms, or both resolved 2 to 63 days following the discontin-
uation of ceftriaxone treatment.
Eight patients treated with ceftriaxone and with gallblad-
der sonograms interpreted as gallstones are known to have
undergone cholecystectomy (unpublished data on file, Hoff-
mann-La Roche, Inc., 1989). One of these patients, an
85-year-old female, had true gallstones. Gallbladders of the
remaining seven patients contained sandlike, semisolid par-
ticles and were reported as "not gallstones."
In this prospective randomized, double-blind, placebo-
controlled trial, 21.4% (6 of 28) of adult patients who
received ceftriaxone developed abnormalities on gallbladder
ultrasound examination. In contrast, one of eight patients
who received placebo developed abnormalities on ultra-
sound examination. Although the differences in the inci-
dence of abnormal gallbladder sonograms in patients who
received ceftriaxone and placebo were not statistically sig-
nificant (P = 0.491), abnormalities were observed on ultra-
sound examination. The gallbladder abnormalities observed
on ultrasound examination were interpreted as gallstones in
five patients and as sludge in two patients (Table 3).
The findings in the eight unevaluable patients with abnor-
mal sonograms at base line add to the complexity of this
phenomenon. The two unevaluable patients who initially
received placebo continued to have positive sonographic
readings following placebo administration and were subse-
quently crossed over to receive ceftriaxone; after a full
course of ceftriaxone, the sonogram in one patient was
unchanged, while in the other the sonogram was interpreted
as cleared. The remaining patients who were unevaluable
received ceftriaxone initially, and no change was demon-
TABLE 3. Ultrasonographic characteristics of patients who developed apparent biliary pseudolithiasis
Patient no. Treatment group Radiologic image Description of image No. Size (mm)
30 Ceftriaxone Echo/shadow (stones) Round/irregular .5 2-10
38 Ceftriaxone Echo/shadow (stones) Round 3 3
41 Ceftriaxone Echo/shadow (stones) Round/irregular .5 3-9
45 Ceftriaxone Echo (sludge) Linear particulate debris >50 1-2
49 Ceftriaxone Echo/shadow (stones) Oval c3 2-7
54 Ceftriaxone Echo/shadow (stone) Oval 1 3
46 Placebo Echo (sludge) Linear particulate debris >50 1-2
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TABLE 4. Characteristics of patients who received ceftriaxone who did and did not develop apparent biliary pseudolithiasisa
Group (no.) Age (yr) Sex (M/Fb) Wt (kg) Treatment(s per day)
With pseudolithiasis (6) 45.0 ± 12.3 0 M/6 F 61.7 ± 6.6 13.7 ± 0.8 32.7 ± 3.5
Without pseudolithiasis (22) 38.4 ± 15.4 8 M/14 F 69.7 ± 13.2 13.8 ± 0.8 26.9 + 10.2
a Values are means ± standard deviations.
b M, Male; F, female.
strated in their sonographic findings after treatment. There-
fore, in this small series of patients, ceftriaxone appeared to
have no enhancing effect on the sonographic image in those
patients with abnormal sonograms prior to therapy.
Ceftriaxone is extensively excreted into the bile (2; G. A.
Gibson, P. R. Audet, G. Morrison, P. P. Soni, and I. H.
Patel, Clin. Pharmacol. Ther. 43:175, 1988). However, there
is a large interpatient variation in absolute bile concentra-
tions. Arvidsson et al. (1) observed a threefold interindivid-
ual variation in the biliary excretion of ceftriaxone. Further-
more, ceftriaxone biliary excretion has been correlated with
the rate of bile acid secretion. If the mechanism of ceftriax-
one-induced pseudolithiasis in humans is precipitation of the
antibiotic in the gallbladder, individuals with increased bile
acid secretion may be predisposed to the development of this
adverse effect.
Because of its excellent antimicrobial spectrum of activity
and attractive pharmacokinetic characteristics, ceftriaxone
is used commonly in patients with serious bacterial infec-
tions. Apparent biliary pseudolithiasis may occur in patients
who receive ceftriaxone. In our study, abnormal gallbladder
sonograms in patients who received ceftriaxone were ob-
served as echos with shadows (five of six patients) and were
interpreted as gallstones. Furthermore, these abnormalities
resolved spontaneously.
Awareness that sonographic interpretations of gallstone
disease in patients who receive ceftriaxone may actually
represent apparent biliary pseudolithiasis, a spontaneously
reversible abnormality, will be conducive toward a conserv-
ative expectant approach to treatment with avoidance of
surgery.
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